Intestinal lipase inhibitors in the treatment of metabolic syndrome in children.

Authors

  • MATRAGUNA Nelea IMSP Institutul de Cardiologie , IMSP Spitalul Clinic Municipal de Copii „Valentin Ignatenco‟
  • TUREA Tatiana Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu‟

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.24

Keywords:

metabolic syndrome, orlistat, obesity, treatment, children, adolescents

Abstract

Obesity and overweight among children and adolescents are accepted worldwide as a chronic multifactorial disorder, with a significant increase in annual prevalence. Abdominal obesity in association with other metabolic risk factors such as hypertension, high cholesterol and triglycerides, as well as low HDL cholesterol are grouped into a syndrome defined as„Reaven syndrome” or „metabolic syndrome”. MetS is often associated with cardiovascular and diabetic risk in children and also with liver damage. Current strategies addressed for the treatment of obesity and metabolic syndrome in children include adequate nutrition, combating sedentary lifestyle, drug therapy, which are used alone, or in combination. These measures are taken to reduce overweight, dyslipidemia, high blood pressure and insulin resistance in children and adolescents.

Author Biographies

MATRAGUNA Nelea, IMSP Institutul de Cardiologie , IMSP Spitalul Clinic Municipal de Copii „Valentin Ignatenco‟

dr. hab. în șt. med., conf. cercetător

TUREA Tatiana, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemițanu‟

rezidentă

References

Elena Fornari, Claudio Maffeis. Treatment of Metabolic Syndrome in Children. Front. Endocrinol., 2019;10:702

Magge SN, Goodman E, Armstrong SC, Nutrition Committee Endocrinology Section Obesity Section. Metabolic syndrome in children and adolescents: shifting the focus to the group of cardiometabolic risk factors. Pediatrics., 2017;140: e20171603. doi: 10.1542 / peds.2017-1603

Francesco Chiarelli, Angelika Mohn: Early diagnosis of metabolic syndrome in children, Published Online August 24, 2017, http://dx.doi.org/10.1016/S23524642(17)30043-3

Anne Ballinger. Orlistat in the treatment of obesity. Expert Opinion on Pharmacotherapy. 2000,1(4): 841-847

Tian-TianLiu, Xiao-TianLiu, Qing-XiChenYanShi: Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother. 2020;128:110314

Yasaman Pirahanchi, Sandeep Sharma. Biochemistry, lipase. https://www.ncbi.nlm.nih.gov/books/NBK537040/

Bai T. et al., Operon for lipstatin biosynthesis, beta-lactone inhibitor of human pancreatic lipase. Applied and Environmental Microbiology, 2014; 80 (24): 7473-7483.

Summary of product characteristics. Xenical. European Medicines Agency. October 2016. https://www.ema.europa.eu/en/medicines/human/EPAR/xenical

CS Elangbam. Current strategies in the development of anti-obesity drugs and their safety issues. https://doi.org/10.1354/vp.46-1-10; 2009.

Xiguang Qi, Sun Yat-sen. Review of the Clinical Effect of Orlistat. IOP Conf. Series: Materials Science and Engineering 301 (2018) 012063.

Early communication on an ongoing safety review of Orlistat (marketed as Alli and Xenical) http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafety Informationfor Patientsand Providers/ucm213038.htm

Wilding J. Orlistat: should we worry about liver inflammation? BMJ, 2013;346:f2777

Amy M. Heck, Jack A. Yanovski, Karim Anton Calis. Orlistat, a New Lipase Inhibitor for the Management of Obesity. Pharmacotherapy, 2000;20(3):270-9

Jaspinder Kaur. A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice. Cardiol Res Pract . 2014;2014:943162.

Susan Z. Yanovski, Jack A. Yanovski. Long-term Drug Treatment for Obesity A Systematic and Clinical Review. JAMA The Journal of the American Medical Association, 2014;1;311(1):74-86

Davies MJ., D’Alessio DA., Fradkin J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2018; 41 (12): 2669-2701.

Sneha Baxi Srivastava. Is there a prescription to treat pediatric obesity? 2019. American Lifestyle of Medicine, 2019; 14(1):36-39

A.K. Al-Suwailem, A.S. Al-Tamimi, M.A. AlOmar and M.S. Al-Suhibani. Safety and Mechanism of Action of Orlistat (Tetrahydrolipstatin) as the First Local Antiobesity Drug. Journal of Applied Sciences Research, 2006; 2(4): 205-208

Kelly L. Matson, PharmD1 and Renee M. Fallon. Treatment of Obesity in Children and Adolescents. J Pediatr Pharmacol Ther, 2012; 17 (1): 45–57.

Jean-Pierre Chanoine, Sarah Hampl, Craig Jensen, Mark Boldrin, Jonathan Hauptman. Effect of Orlistat on Weight and Body ,Composition in Obese Adolescents. A Randomized Controlled Tria. JAMA,2005; 293:232.

Khera R., Murad MH., Chandar AK., Dulai PS., Wang Z., Prokop LJ. et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Jama. 2016;315(22):2424-34.

Gadde KM., Pritham Raj Y. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. Current diabetes reports. 2017;17(5):34.

Zimmet P, Alberti KG, Kaufman F. et al; Grupul de consens IDF. Sindromul metabolic la copii și adolescenți un raport de consens IDF. Diabet Pediatr. 2007; 8(5):299-306

Wittcopp C., Conroy R. Metabolic syndrome in children and adolescents. Pediatr Rev. 2016;37(5):193-202.

Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl Pediatr. 2017;6(4):397-407.

Mhatre SV., Bhagit AA., Yadav RP. Pancreatic Lipase Inhibitor from Food Plant: Potential Molecule for Development of Safe Anti-obes ity Drug. MGM J Med Sci 2016;3(1):34-41.

Published

2022-04-08